Mechanism of action of inhibitors of MRTF/SRF-regulated gene transcription

This study reports a promising small-molecule compound that targets the transcriptional machinery driving melanoma spread by blocking MRTF/SRF-regulated gene expression. Their work repurposes a compound originally investigated for scleroderma, an autoimmune fibrosis condition, and demonstrates potent anti-migration and anti-metastatic effects in melanoma models. The research shows the compound interferes with the ability of Myocardin-related transcription factors (MRTFs) to initiate transcription, a step downstream of RhoC signaling that is known to promote aggressive melanoma behavior. By screening intact melanoma cells, Neubig's team identified inhibitors that can act at multiple points along the RhoC-to-MRTF pathway, enabling discovery of small molecules that prevent MRTF activation and subsequent transcriptional programs that enable tumor cell migration.

The compound reduced melanoma cell migration by 85 to 90 percent in cellular assays and markedly decreased tumor burden in the lungs of mice injected with human melanoma cells, indicating efficacy against metastatic colonization. These findings highlight MRTF-driven transcription as an actionable target in melanoma and position MRTF activation as a potential biomarker to identify patients most likely to benefit. The researchers emphasize that the compound's effects are stronger when the MRTF pathway is activated in tumors, suggesting a precision-medicine approach: patients with evidence of RhoC/MRTF pathway activation could be selected for treatment with MRTF inhibitors. Because melanoma mortality is largely driven by metastatic spread, with survival dropping steeply when disease is diagnosed at later stages, agents that block migration and dissemination could substantially improve outcomes.

Developing small molecules capable of disrupting transcriptional signaling is challenging, but the identified compound successfully limits the transcriptional output of MRTFs, a class of coactivators that respond to cytoskeletal and Rho-family signaling. The compound's mechanism is important because it targets a signaling cascade that links extracellular and intracellular cues to gene expression programs that promote invasion and metastasis. The researchers leveraged phenotypic screening of whole melanoma cells, which allowed detection of inhibitors acting at various junctures of the pathway rather than being limited to a single protein target. This strategy enabled identification of the MRTF signaling protein as a viable node for therapeutic intervention.

The study was supported by the National Institutes of Health and by funds raised through MSU's Gran Fondo cycling event benefiting skin cancer research. Neubig and colleagues propose next steps including development of biomarkers to detect MRTF pathway activation in patient tumors and further preclinical optimization of the compound. Their work demonstrates a translational path from basic mechanistic insight, RhoC-driven activation of MRTF/SRF-regulated transcription, to a small-molecule inhibitor that significantly reduces melanoma migration and lung metastases in preclinical models, offering a potential new strategy to limit melanoma dissemination and improve patient survival.